Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Empress Therapeutics logo — Medicines from within

Empress Therapeutics

Medicines from within

Founded 2022 United States Watertown, United States 18 employees Venture round Total: $50.00M AI, Biotechnology

General Information

Company Name Empress Therapeutics
Founded Year 2022
Location United States Watertown, United States
Employees 18
Industries AI, Biotechnology
Funding Stage Venture round
Business Model B2B, Platform, B2B2C
Revenue Model Licensing, Performance Based, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Empress Therapeutics. To contact Empress Therapeutics, visit empresstx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Empress Therapeutics compare?

A PDF of Empress Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Empress Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Acquired Oct 29, 2026

Flagship Pioneering announced the formation of Etcelera, bringing together Cellarity, Empress Therapeutics, and Etiome.

Empress Therapeutics a competitor of yours? Have our desk watch it

About Empress Therapeutics

Empress Therapeutics, headquartered in the United States, is a pioneering company in the intersection of AI and Biotechnology. Founded in 2020 by Flagship Pioneering, the company is on a mission to create "Medicines from within".

Their innovative Empress Chemilogics(TM) platform uniquely leverages human DNA to develop cutting-edge oral medicines designed to be first- or best-in-class. The approach promises to produce treatments for a broad array of diseases more rapidly, predictably, and cost-effectively than traditional methods.

The company recently secured a $50.00M investment in a Venture Round on 21 June 2023, with continued backing from Flagship Pioneering. This funding highlights the ongoing confidence in Empress Therapeutics' novel methodology and potential to disrupt the pharmaceutical industry.

Business keywords: Drug Development, Chemilogics Platform, DNA Insights, Oral Medicines, Genetic Data, Endogenous Molecules, Small-molecule Drug Candidates, Unmet Medical Needs, Human Molecular Data, Evolutionary Biology, Proprietary Bio Platform, Molecular Insights, Flagship Pioneering

Services & Products

AI-driven drug discovery
Chemilogics platform utilization
Genetic data analysis
Synthetic biology applications

Target Customers

Pharmaceutical companies Biotechnology firms Medical researchers

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $50.00M 1
Flagship Pioneering
Flagship Pioneering
21 Jun 2023

Empress Therapeutics Alternatives & Competitors

View All Alternatives
Empress Therapeutics vs
DeepCure
DeepCure United States

Reimagining small molecule therapies for immune diseases

Series A
28 employees
AI, Biotechnology
Compare Empress Therapeutics vs DeepCure
Empress Therapeutics vs
Silexon AI
Silexon AI China

AI Empowers Drug Discovery and Life Sciences

Series A
5 employees
AI, Biotechnology
Empress Therapeutics vs
BlackThorn Therapeutics
BlackThorn Therapeutics

Pioneering precision medicine for CNS disorders through advanced computational and clinical neurosci...

Series B
AI, Biotechnology
View all alternatives

FAQ About Empress Therapeutics

Medicines from within
Empress Therapeutics was founded in 2022.
Empress Therapeutics is headquartered in Watertown, United States.
Empress Therapeutics operates in AI and Biotechnology. Its work centres on Drug Development, Chemilogics Platform, DNA Insights and Oral Medicines. Its customers include Pharmaceutical companies, Biotechnology firms and Medical researchers.
Empress Therapeutics has a B2B, Platform and B2B2C business model. Its revenue comes from Licensing, Performance Based and Project Based.
Empress Therapeutics has approximately 18 employees.
Empress Therapeutics has completed 1 funding round, raising a total of $50.00M. The latest funding stage is Venture round.
Empress Therapeutics offers: AI-driven drug discovery, Chemilogics platform utilization, Genetic data analysis, Synthetic biology applications.
Top alternatives and competitors to Empress Therapeutics include DeepCure, Silexon AI, BlackThorn Therapeutics, 1910 Genetics, Iambic. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Empress Therapeutics and DeepCure are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Empress Therapeutics, https://bouncewatch.com/company/empress-therapeutics, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout